Sphingosine kinase 1 (SK1) phosphorylates sphingosine to form sphingosine 1-phosphate (S1P), which has the ability to promote cell proliferation and survival and stimulate angiogenesis. The SK1/S1P pathway also plays a critical role in regulation of cyclooxygenase-2 (COX-2), a wellestablished pathogenic factor in colon carcinogenesis. Therefore, we examined the expression of SK1 and COX-2 in rat colon tumors induced by azoxymethane (AOM) and the relationship of these two proteins in normal and malignant intestinal epithelial cells. Strongly positive SK1 staining was found in 21/28 (75%) of rat colon adenocarcinomas induced by AOM, whereas no positive SK1 staining was observed in normal mucosa. The increase in SK1 and COX-2 expression in AOM-induced rat colon adenocarcinoma was confirmed at the level of mRNA by real-time RT-PCR. In addition, it was found that 1) down-regulation of SK1 in HT-29 human colon cancer cells by small interfering RNA (siRNA) decreases COX-2 expression and PGE 2 production; 2) overexpression of SK1 in RIE-1 rat intestinal epithelial cells induces COX-2 expression; and 3) S1P stimulates COX-2 expression and PGE 2 production in HT-29 cells. These results suggest that the SK1/S1P pathway may play an important role in colon carcinogenesis, in part, by regulating COX-2 expression and PGE 2 production.
play key roles as signaling molecules (1, 2) . In particular, three of these sphingolipid metabolites, ceramide, sphingosine and sphingosine 1-phosphate (S1P), have recently emerged as a new class of lipid messengers that regulate cell proliferation, differentiation, and survival in opposite directions (3) (4) (5) . S1P promotes cell proliferation and survival, whereas sphingosine and ceramide inhibit cell proliferation and stimulates apoptosis. In addition, S1P is a novel regulator of angiogenesis (6) . The balance of these three important lipid signal molecules is critically regulated by sphingosine kinase (SK), which converts sphingosine to S1P by phosphorylating sphingosine. Two SK isoforms have been cloned and characterized to date (7) (8) (9) . SK1, the agonist-inducible isoform that can be activated by a variety of growth factors, cytokines and mitogens, has been implicated in cell transformation and tumor growth and is critically involved in the oncoprotein Ras-mediated oncogenesis. For example, NIH3T3 cells transfected with human SK1 cDNA acquires the transformed phenotype and has the ability to form tumors in NOD/SCID mice (10) . Overexpression of SK1 promotes tumorigenesis of MCF-7 breast cancer cells in nude mice, probably by conferring a growth advantage to these cells and augmenting neovascularization of the tumor (11) . In contrast, inhibition of SK1 activity with nonspecific SK inhibitor, N, N-dimethylsphingosine (12) , or the dominant-negative mutant SK1 G82D (13) , significantly reduced Ras-induced cell transformation and suppressed the growth of several types of tumor cells in vivo and in vitro by inhibiting cell proliferation and promoting apoptosis.
Recently, Pettus et al. (14) reported that down-regulation of SK1 but not SK2 using specific small interfering RNAs (siRNAs) abolished the ability of tumor necrosis factor-α (TNF-α) to induce cyclooxygenase-2 (COX-2) expression and prostaglandin E 2 (PGE 2 ) production in L929 murine fibrosarcoma and A549 human lung carcinoma cells. In contrast, cells treated with siRNAs targeting S1P lyase and S1P phosphatase (two main S1P degradation enzymes) increased TNF-α-induced COX-2 expression, leading to an augmented production of PGE 2 . These findings suggest that SK1 and S1P may play an important role in the regulation of COX-2 expression and PGE 2 production. Increased expression of COX-2 and production of PGE 2 have been implicated in colon carcinogenesis in humans and rodents (15) (16) (17) (18) . Inhibition of COX, particularly COX-2, reduces colon cancer development (19) , whereas administration of PGE 2 augments colon carcinogenesis (20) .
Therefore, we hypothesize that the SK1/S1P pathway may play an important role in colon carcinogenesis, in part by regulating COX-2 expression and PGE 2 production. The present study was aimed to test this hypothesis using a well-established rat colon carcinogenesis model induced by azoxymethane (AOM) and using small interfering RNA (siRNA) and gene transfection techniques to down-and up-regulate SK1 expression in HT-29 human colon cancer cells and RIE-1 rat intestinal epithelial cells, respectively.
MATERIALS AND METHODS

In vivo animal experiment
Tumor samples
A total of 24 F344 male rats (Charles River Lab. Inc., Wilmington, MA) were treated with AOM (Sigma, St. Louis, MO) to induce colon tumors using the same protocol as previously reported (19) . Briefly, at age of 7 weeks, rats received subcutaneous injections of AOM (15 mg/kg body wt) once a week for 2 weeks. Six untreated mice were included as a control. The rats were maintained on a control diet (modified AIN-76A) until termination of the experiment. Animals were weighed every week for the first 8 weeks and then every 4 weeks and monitored daily for their general health. The experiment was terminated at 50 weeks after the second AOM treatment, at which time all animals were killed by CO 2 euthanasia. After laparotomy, the entire intestines were resected and opened longitudinally, flushed with normal saline to remove the intestinal contents. Colon tumors were fixed in 10% buffered formalin, embedded in paraffin blocks, and processed for histological evaluation by routine procedures with H&E staining. Serial sections of these tumors were used for immunohistochemical staining. Colon tumors, including 9 adenomas and 28 adenocarcinomas (17 well differentiated, 6 moderately differentiated and 5 poorly differentiated adenocarcinomas), were found in 24 rats treated with AOM. Multiplicities of colon tumors (number of tumors/rat) were 0.38 ± 0.49 for adenoma and 1.17 ± 0.96 for adenocarcinoma. All colon tumors were examined for SK1 and COX-2 immunohistochemistry with paired normal mucosa. In addition, five frozen paired colon mucosa and cancers were collected from AOM-treated rats for the analysis of SK1 and COX-2 mRNA expression using real-time RT-PCR. The frozen samples of colon mucosa were collected by scraping the normal appearing mucosa from AOM-treated male F344 rats. The frozen colon tumors diagnosed as adenocarcinoma by H&E histological evaluation were harvested from the same samples. All of these animal procedures were performed with the approval of the Institutional Animal Care and Use Committee at the Medical University of South Carolina (MUSC).
Preparation of mouse monoclonal antibody against SK1
The monoclonal antibody directed against human SK1 was prepared by the MUSC Antibody Facility. Briefly, a synthetic oligopeptide corresponding to the past 20 amino acids of the Cterminal (CVEPPPSWKPQQMPPPEEPL) of human SK1 (GenBank accession no. AAF73423) was conjugated to keyhole limpet hemocyanin (KLH) and injected subcutaneously (30 μg/mouse) into 8-wk-old male BALB/c mice (Charles River Lab. Inc.) in 0.1 ml complete Freund's adjuvant. After the initial immunization, mice were boosted by intraperitoneal injections with the same antigen (30 μg/mouse) in incomplete Freund's adjuvant every 3 wk. Seven days after each booster immunization, serum antibody titers were measured by enzymelinked immunosorbent assay (ELISA) using the plates coated with the synthetic SK1 oligopeptide. Mice with higher titer of the antibody were selected and given a final immunization. Spleen cells were isolated and fused with mouse myeloma SP2/0 cells using polyethylene glycol 1500 (Roche, Indianapolis). Hybridomas were selected by HAT medium (hypoxanthine, aminopterin, thymidine) and screened by ELISA for specificity to the peptide. The positive hybridomas were cloned three times by limiting dilution. The subclasses of the monoclonal antibodies were determined using mouse monoclonal antibody isotyping reagents from Sigma.
Immunohistochemistry
All immunohistochemical analyses were carried out with the avidin-biotin complex immunoperoxidase technique. Tissue sections (5 μm) were mounted on glass slides, deparaffinized with xylene, and rehydrated with graded alcohol. After blocking endogenous peroxidase with 3% hydrogen peroxide in methanol for 10 min, slides were immersed in 10 mM citrate buffer (pH 6) and placed in a steamer for 30 min to enhance antigen exposure. Then, slides were incubated with 2% normal host serum of secondary antibody in PBS containing 0.3% Triton X-100 for 30 min. SK1 mouse monoclonal antibody and a goat polyclonal antibody against COX-2 (Santa Cruz Biotechnology, Santa Cruz, CA) were used as the primary antibodies for the immunostaining at 1:100 dilution. Biotinylated horse anti-mouse IgG and biotinylated rabbit anti-goat IgG were employed as the secondary antibodies at 1:200 dilution, respectively. The immunostaining was developed using Vectastain ABC reagents (Vector Laboratories, Burlingame, CA), 3,3′-diaminobenzidine and hydrogen peroxide. The tissue sections were counterstained with hematoxylin. As a control for SK1 and COX-2 immunohistochemistry, duplicate sections were immunostained with the SK1 antibody that was preincubated with the SK1 oligopeptide or stained without the primary COX-2 antibody, respectively. The levels of immunohistochemical staining for SK1 and COX-2 are described as follows: negative, no staining; +/−, weak staining in <50% of the cells; positive, moderate to strong staining >50% of the cells.
Immunoblot analysis
Tissue and cellular lysates were prepared as described before (21) . Briefly, tissues and pelleted cells were lysed in ice-cold 0.1 M phosphate buffer (pH 7.4) containing 20% glycerol, 1 mM mercaptoethanol, 1 mM EDTA, phosphatase inhibitors (1 mM sodium orthovanadate, 15 mM sodium fluoride), protease inhibitors (10 μg/ml each leupeptin, aprotinin, trypsin, chymotrypsin, and 1 mM phenylmethylsulfonyl fluoride) and 0.5 mM 4-deoxypyridoxine using a homogenizer. The protein concentrations of these lysates were quantified using a Bio-Rad protein assay reagent (Bio-Rad Laboratories, Hercules, CA). An equal amount of protein (40 μg) from each lysate was resolved on 10% polyacrylamide gels (SDS-PAGE) under denaturing conditions and then transferred to polyvinylidene difluoride membranes (Immuno-Blot PVDF membrane, BioRad Laboratories). After overnight blocking with 5% nonfat milk in Tris-buffered saline containing 0.1% Tween 20, the membranes were probed with the mouse monoclonal anti-human SK1 antibody or a goat polyclonal antibody against human COX-1, COX-2, or β-actin (Santa Cruz Biotechnology, Santa Cruz, CA). Subsequently, the membranes were incubated with an appropriate horseradish peroxidase-conjugated secondary antibody and visualized using the ECL immunoblotting detection system (Amersham Biosciences, Piscataway, NJ). To verify the relative protein amounts in each lane, the levels of β-actin were determined as an internal control.
Real-time RT-PCR
RNA was extracted from five frozen paired colon mucosa and cancers collected from AOMtreated male F344 rats as described above using a guanidium thiocyanate-phenol-chloroform solution (RNA STAT-60, TEL-TEST, Friendswood, TX) per the manufacturer's instructions. cDNA was synthesized from 5 μg of total RNA using M-MLV reverse transcriptase (Promega, Madison, WI) and oligo d(T) [12] [13] [14] [15] [16] . Real-time RT-PCR was performed on a PE Applied Biosystems Gene Amp 5700 Sequence Detection System (Foster City, CA) to quantify the levels of SK1 and COX-2 mRNA. The standard real-time RT-PCR reaction volume was 10 μl, including 4.2 μl QuantiTest SYBR Green PCR reagents (Qiagen, Valencia, CA), 0.1 μl AmpErase UNG enzyme (PE Applied Biosystems), 0.7 μl cDNA template, 0.8 μl forward primer (3.125 μM), 0.8 μl reverse primer (3.125 μM), and 3.4 μl water. The following primers were used for PCR
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amplification: SK1 forward primer 5′-CCGTACTTGGTTCATGTGCCA-3′, and reverse primer 5′-TCCCCGTCCACAGAAAACACT-3′; COX-2 forward primer 5′-TGAGTACCGCAAACGCTTCTC-3′, and reverse primer 5′-TGCAGCCATTTCTTTCTCTCCT-3′; β-actin forward primer 5′-TAAGGCCAACCGTGAAAAGATG-3′, and reverse primer 5′-CTGGATGGCTACGTACATGGCT-3′. Initial steps of RT-PCR were 2 min at 50°C for AmpErase UNG enzyme activation, followed by a 10-min hold at 95°C for its deactivation. Cycles (n=40) consisted of a 15-s melt at 95°C, followed by 1 min annealing/extension at 60°C. The final step was 1 min incubation at 60°C. All reactions were performed in triplicate. Threshold cycle (CT) analysis for all samples was set at 0.15 relative fluorescence units.
The data were analyzed using Q-Gene software (22) and expressed as mean normalized expression (MNE). MNE is directly proportional to the amount of RNA of the target gene (SK1 or COX-2) relative to the amount of RNA of the reference gene β-actin.
In vitro cell culture experiment
Cell culture, cytokines, and sphingolipids HT-29 human colon adenocarcinoma cell line was purchased from ATCC (Rockville, MD). RIE-1 rat intestinal epithelial cells were a gift from K. D. Brown (Babraham Institute, Cambridge, UK). Cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA) in a 5% CO 2 atmosphere with saturated humidity. Human recombinant TNF-α and IL-1β were purchased from PeproTech. (Rocky Hill, NJ) and R&D Systems (Minneapolis, MN), respectively. S1P was obtained from Sigma. Sphingosine, C 16 ceramide, and all the C 17 backbone-labeled sphingolipids (S1P, ceramide and sphingosine) were synthesized in the Lipidomics Core Facility at MUSC.
RNA interference
The gene silencing of human SK1 was performed essentially as described before using sequence specific siRNA reagents (Qiagen, Valencia, CA) (23) . The human SK1 (24) silencing target starts at the 70th nucleotide from the start codon. The sequences of the sense and anti-sense siRNAs are GGGCAAGGCCUUGCAGCUCdTdT and GAGCUGCAAGGCCUUGCCCdTdT; and these of scramble control siRNAs (SCR) are CUGGUUACGAAGCGAAUCCdTdT and GGAUUCGCUUCGUAACCAGdTdT. The specificity of SK1 siRNA was verified by sequence comparison with the human genome database using the NIH blast program. To down-regulate SK1 expression, HT-29 cells were seeded in 6-well plates at a concentration of 50,000 cells per well. After one-day incubation, they were transfected with 200 nM of SK1 siRNA or SCR using OligofectAMINE (Invitrogen) as recommended by the manufacturer. After 48 h of transfection, some of the cells were harvested for the analysis of SK1 expression and the others were treated with vehicle, TNF-α (5 nM) or IL-1β (2.5 ng/ml) to stimulate COX-2 expression and PGE 2 production.
Transfection of human SK1 in RIE-1 cells
The human SK1 expression plasmids were constructed as described in the previous study (21) . RIE-1 cells were transfected with human SK1 plasmids (RIE-S) or empty vector plasmids (RIE-N) using LipofectAMINE 2000 (Invitrogen) according to the manufacturer's instructions. Stable
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cell lines were established by maintaining the cells in culture with 1.5 mg/ml G418 (Invitrogen) in media.
Measurement of PGE 2 levels
The culture supernatants of HT-29 cells were collected after they were incubated with vehicle, TNF-α or IL-1β for 4 h as described above and assayed for PGE 2 production using a prostaglandin E 2 monoclonal enzyme immunoassay (EIA) Kit from Cayman Chemical (Ann Arbor, MI) according to the manufacturer's instructions. The results are expressed as picograms per milliliter calculated according to the PGE 2 standard curve. All assays were performed in triplicate.
Sphingosine kinase activity assay
The activity of sphingosine kinase was measured as described previously (14) . Briefly, cellular lysates were prepared as described above. An aliquot of the cell lysates containing 100 μg proteins was assayed for sphingosine kinase activity by incubation of the cell lysates with sphingosine and [γ-
32 P]ATP for 30 min at 37°C. The reaction products were separated on a silica gel G60 TLC plate (Whatman, Clifton, NJ) using 1-butanol/methanol/acetic acid/water (80:20:10:20) as the mobile phase and visualized by autoradiography. The radioactive spots corresponding to S1P were scraped and counted in a scintillation counter.
Incubation with C 17 backbone-labeled sphingolipids and sphingolipid profiling
C 17 backbone-labeled S1P, ceramide, or sphingosine were dissolved in 0.1% ethanol/0.002% dodecane mixture and then diluted with cell culture medium. HT-29 cells were pulsed with increasing concentrations (0.5 to 5 μM) of these sphingolipids for various durations (15 to 60 min). The uptake of these sphingolipids was analyzed by sphingolipid profiling using the positive mode electrospray ionization (ESI)/MS/MS analysis in the Lipidomics Core Facility at MUSC as described before (14) . The major species of cellular ceramide include C 16 and C 24 ceramide as previously reported, but the data for ceramide are presented as total ceramide by adding all the different species of ceramide together. The results are expressed as picomoles sphingolipids/nanomole lipid phosphate (Pi).
Data Analysis
Results of levels of PGE 2 and real-time RT-PCR were analyzed by the paired Student's t test. Differences were considered statistically significant at P < 0.05.
RESULTS
AOM up-regulates the expression of SK1 and COX-2 in colon carcinogenesis
The expression of SK1 in AOM-induced colon carcinogenesis was examined by immunohistochemistry using a mouse monoclonal antibody. As shown in Fig. 1A , the SK1 antibody is highly specific to SK1, as it only detected a single band in the immunoblot analysis for the lysates of HEK293 cells transfected with the human SK1 plasmids (21) . The immunoblot signal disappeared if the antibody was preabsorbed with the immunized oligopeptides. In addition, no immunoblot signal was detected by the antibody in the lysates from HEK293 cells transfected with the control vector plasmids. Cross reactivity of the SK1 antibody with rat SK1 was confirmed by Western blot analysis (Fig. 1B) . The antibody only detected a single band with the respective molecular weight of 47 kD corresponding to rat SK1 in the lysates from the rat kidney and colon (25) . In immunohistochemical analysis, rat SK1 positive staining was diminished by preabsorbing the antibody with the SK1 oligopeptides (Fig. 1C) . These results confirmed that this mouse monoclonal antibody can specifically recognize both rat and human SK1 proteins. In addition, the immunohistochemical results of SK1 staining with the mouse antibody were confirmed by using polyclonal antibodies against human (21) and mouse SK1 (25) (data not shown).
A preliminary study showed that SK1 immunostaining was undetectable in normal mucosa but visible in vascular endothelial cells of normal colon tissues. This finding is in agreement with a previous study showing that human normal intestinal mucosa was weakly stained for SK1, whereas endothelial cells of blood vessels in almost all human tissues were positively stained for SK1 using a rabbit polyclonal SK1 antibody (25) . Similarly, SK1 expression was barely detectable in the normal epithelium adjacent to colon adenocarcinoma (Fig. 1D) . In contrast, colon adenocarcinoma cells (solid arrows) along with some of stromal cells (yellow arrow) and vascular endothelial cells (red arrow) were positively stained for SK1 (Fig. 1E, left) . The immunoreactivity of SK1 was localized in the cytoplasm, primarily in the perinuclear regions of adenocarcinoma cells (Fig. 1E, left) .
Subsequently, we examined SK1 expression in colon carcinogenesis induced by AOM. In addition, the relationship between SK1 and COX-2 expression in AOM-induced colon tumors was also examined because SK1 has been implicated in the regulation of COX-2 expression and COX-2 is induced in colon carcinogenesis. The immunoreactivity of both SK1 and COX-2 exhibited a similar cellular distribution, as COX-2 positive staining was also observed in cancer cells, vascular endothelial cells, and inflammatory cells (Fig. 1E, right) .
We next extended this approach to various sequential stages in colon carcinogenesis, e.g., adenomas and adenocarcinomas (including well, moderately, and poorly differentiated adenocarcinomas). Figure 2 shows representatives of H&E staining and SK1 and COX-2 immunohistochemistry in colon adenoma and adenocarcinoma. The numbers of the tumors examined were 9 adenomas and 28 adenocarcinomas (17 well, 6 moderately, and 5 poorly differentiated adenocarcinomas) induced by AOM in 24 male F344 rats. The immunostaining results are summarized in Table 1 . Two out of nine adenomas stained weakly for SK1 ( Fig. 2A) , and these two tumors were negative for COX-2 staining. Two other adenomas were stained weakly for COX-2. Thus, adenomas show very low levels of SK1 and COX-2 staining. These findings are in agreement with our previous study on COX-2 expression in colon carcinogenesis (26) .
In contrast, ~10% (3/28) and 75% (21/28) adenocarcinomas demonstrated weak and positive staining for SK1, respectively. Specifically, SK1 positive staining was observed in 76% (13/17) of well-differentiated adenocarcinomas (Fig. 2B) , 83% (5/6) of moderately differentiated adenocarcinomas (Fig. 2C) , and 60% (3/5) of poorly differentiated adenocarcinomas (Fig. 2D) . Similarly, 50% (14/28) of adenocarcinomas indicated positive staining for COX-2, including 71% (12/17) of well-differentiated, 33% (2/6) of moderately differentiated, but none (0/5) of
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poorly differentiated adenocarcinomas. The ratio of COX-2 positive staining in colon tumors from the present study is consistent with our previous study (26) . It is noteworthy that all COX-2 positively stained adenocarcinomas exhibited positive SK1 staining. These results suggest that COX-2 appears to be induced in a subset of the SK1 expressing tumors and that SK1 expression may be associated with the induction of COX-2 in AOM-induced colon carcinogenesis.
To investigate whether AOM up-regulates the expression of SK1 and COX-2 at the level of RNA, the expression of SK1 and COX-2 mRNA in normal colon mucosa and adenocarcinomas induced by AOM was determined by quantitative real-time RT-PCR. The results of SK1 and COX-2 mRNA expression in normal colon mucosa and cancer tissues are expressed as MNE by normalization to the expression of the reference gene (β-actin) and are presented in Fig. 3 . The data show that both SK1 and COX-2 mRNA were significantly overexpressed in colon cancer tissues as compared with normal mucosa (P<0.001 and P<0.01, respectively).
Down-regulation of SK1 expression by siRNA decreases COX-2 expression and PGE 2 production in HT-29 cells
To investigate whether SK1 is involved in the regulation of COX-2 expression and PGE 2 production in colon adenocarcinoma cells, the levels of SK1 were down-regulated by transfection of HT-29 cells with siRNAs, specifically targeting human SK1. A preliminary study showed that transfection of HT-29 cells with 25, 50, 100, and 200 nM of SK1 siRNA dosedependently reduced the SK activity induced by IL-1β by 25, 36, 75, and 82%, respectively, as compared with the cells treated with 200 nM of scrambled (SCR) siRNA (data not shown). Therefore, 200 nM siRNA was selected for the subsequent study. As shown in Fig. 4A , transfection of HT-29 cells with SK1 siRNA at 200 nM resulted in ~75% reduction in SK1 protein expression as compared with the cells transfected with SCR siRNA. Importantly, the down-regulation of SK1 expression by siRNA nearly completely inhibited TNF-α-or IL-1β-induced COX-2 protein expression, but it had no significant effect on the constitutive expression of COX-1 (Fig. 4B) . Correspondingly, the production of PGE 2 by HT-29 cells stimulated with TNF-α or IL-1β was significantly reduced by down-regulation of SK1 (Fig. 4C) . In contrast, down-regulation of SK2 by transfection of the cells with SK2 siRNA did not produce any inhibitory effects on TNF-α-or IL-1β-induced COX-2 expression and PGE 2 production (data not shown). These results suggest that SK1 but not SK2 may mediate the induction of COX-2 expression and PGE 2 production by the inflammatory cytokines in colon cancer cells.
SK1 overexpression induces COX-2 expression in rat intestinal epithelial cells
Next, we examined whether overexpression of SK1 induces COX-2 expression in intestinal epithelial cells. RIE-1 rat intestinal epithelial cells were stably transfected with pEGFP-human SK1 (RIE-S cells) or empty vector plasmids (RIE-N cells). Immunoblot analysis confirmed that RIE-S cells constitutively express the EGFP epitope-tagged human SK1, which was not detectable in RIE-N and untransfected RIE-1 cells (Fig. 5C ). The SK activity was ~10 times greater in RIE-S cells than that in RIE-N cells (Fig. 5A) . The intracellular level of S1P was also increased ~3.4-fold in RIE-S cells as compared with that in RIE-N cells (Fig. 5B) . The expression of SK1 in RIE-S cells was further increased by the stimulation with TNF-α or IL-1β. Interestingly, COX-2 expression was found in RIE-S cells but not in RIE-N cells under basal conditions (Fig. 5D) . Upon TNF-α or IL-1β stimulation, the expression of COX-2 was further 
S1P induces COX-2 expression and PGE 2 production in HT-29 cells
To determine whether S1P acts downstream of SK1, we incubated HT-29 cells with C 17 backbone S1P and then analyzed the expression of COX-2 and production of PGE 2 . In addition, the cells were incubated with C 17 backbone ceramide and sphingosine as controls. The dodecaneethanol method was used to facilitate the uptake of these sphingolipids by the cells. A preliminary study showed that all these sphingolipids can be effectively taken up by the cells in a time-dependent manner (data not shown). The peak uptake of these sphingolipids occurred at 30 min after the incubation, and their intracellular levels decreased at 60 min, probably as a result of their metabolism (data not shown). The uptake of C 17 backbone ceramide resulted in about a twofold increase in intracellular ceramide with no changes in the levels of sphingosine and S1P (Fig. 6A) . Interestingly, incubation of the cells with exogenous sphingosine resulted in a slight increase in the intracellular level of sphingosine but more than a fivefold increase in ceramide. However, no increase in S1P was found in the sphingosine-treated cells, indicating that sphingosine is rapidly converted to ceramide but not to S1P when it is taken up by cells. In contrast, incubation of the cells with S1P resulted in a dramatic increase in the level of intracellular S1P with some conversion to ceramide (Fig. 6A) . Interestingly, it was found that only the cells incubated with exogenous S1P exhibited dose-dependent induction of COX-2 expression and PGE 2 production, whereas incubation of the cells with ceramide and sphingosine did not have any effect (Fig. 6B and C) . These results demonstrate that S1P, but not ceramide or sphingosine, may act downstream of SK1 to induce COX-2 expression and PGE 2 production in HT-29 cells.
DISCUSSION
The oncogenic potential of SK1 has been well documented in cultured cells employing the gene transfection technique. However, the role of SK1 in cancer development in vivo has not been examined. Therefore, in the present study, we examined whether SK1 is up-regulated during colon carcinogenesis in a rodent colon cancer model induced by AOM. AOM is a wellcharacterized carcinogen that induces colon cancer in rodents following intraperitoneal or subcutaneous injection. The induction of colon cancer by AOM in rats mimics the process of human colon carcinogenesis, e.g., via a chronologically progressive manner from aberrant crypt foci, adenoma to adenocarcinoma.
The results from this study showed that AOM-induced colon carcinogenesis is associated with an up-regulation of SK1 expression, particularly in a tumor progressive manner. Specially, no SK1 immunostaining was observed in normal colon mucosa that were either from normal rats or adjacent to colon adenocarcinomas. Low percentage (<22%) of colon adenomas showed weak staining for SK1. In contrast, ~86% of colon adenocarcinomas exhibited weak (3/28) to intense (21/28) SK1 immunostaining. The up-regulation of SK1 expression by AOM in colon carcinogenesis is likely at the level of transcription as the analysis of SK1 mRNA expression by real-time RT-PCR demonstrated that colon adenocarcinoma induced by AOM expressed a significantly greater level of SK1 mRNA than that of adjacent normal mucosa. This result is consistent with a recent report that human cancer tissues, including colon cancer expressed higher levels of SK1 mRNA than their respective normal controls (27) . However, the mechanism of induction of SK1 expression during colon carcinogenesis has yet to be elucidated.
Because SK1 is mainly up-regulated in colon adenocarcinomas, the results imply that the upregulation of SK1 may be associated with malignant transformation of colon tumors from adenomas to malignant adenocarcinomas. This suggestion is supported by the finding that NIH3T3 cells ectopically transfected with SK1 acquire the transformed phenotype, including focus formation, colony growth in soft agar, and the ability to form tumors in SCID mice (10) . In addition to rat colon cancer tissues examined in the present study, increased SK1 immunostaining was also observed in the majority of human colon adenocarcinomas (unpublished data). These results suggest that increased SK1 expression in colon carcinogenesis is not restricted to this rodent model. A more detailed investigation of SK1 expression in human colon cancer is ongoing.
The mechanisms by which SK1 promotes carcinogenesis probably depend on its ability to phosphorylate sphingosine to produce S1P. S1P has the ability to promote cell survival and proliferation and stimulate angiogenesis. The effect of S1P on COX-2 expression is of a particular interest to colon cancer because overexpression of COX-2 has been implicated in colon carcinogenesis. However, the upstream signals that regulate COX-2 expression during colon carcinogenesis are not known. Therefore, we further investigated the relationship between SK1 and COX-2 expression in AOM-induced colon carcinogenesis. It was found that ~50% (14/28) of AOM-induced colon adenocarcinomas showed positive staining for COX-2. Interestingly, all these COX-2 positive tumors also exhibited SK1 staining. This result suggests that there is a close correlation between SK1 and COX-2 expression in colon carcinogenesis.
It has been reported that SK1 can mediate the induction of COX-2 expression, suggesting that there may be a mechanistic link between SK1 and COX-2 expression in colon carcinogenesis. In support of this suggestion, we found that down-regulation of SK1 in HT-29 human colon cells significantly inhibited COX-2 expression and PGE 2 production induced by TNF-α or IL-1β, whereas overexpression of SK1 in rat RIE-1 intestinal epithelial cells increased the expression of COX-2 and augmented TNF-α-or IL-1β-induced COX-2 expression. The effect of SK1 on COX-2 expression and PGE 2 production is likely mediated by S1P, because overexpression of SK1 in RIE-1 cells up-regulates intracellular levels of S1P. In addition, incubation of HT-29 cells with exogenous S1P, but not with ceramide or sphingosine, induces PGE 2 production, even though all these sphingolipids can be effectively taken up by the cells. However, in spite of all these in vitro observations, the role of the SK1/S1P pathway in regulation of the COX-2/PGE 2 pathway in colon carcinogenesis has yet to be validated in vivo in an animal model.
Despite an increase in intracellular levels of S1P in SK1 overexpressing RIE-S cells, there was no detectable S1P secretion into extracellular culture media by the cells (data not shown), which is consistent with the previous studies showing that NIH3T3 or HEK293 cells transfected with SK1 were unable to secrete S1P (10, 28) . These findings suggest that S1P may regulate COX-2 via a yet unidentified intracellular receptor. Significant increase in the levels of intracellular S1P was also found in HT-29 cells incubated with exogenous S1P. It is likely that the effect of exogenously added S1P on COX-2 expression and PGE 2 production in HT-29 cells may be, in part, mediated through intracellular S1P receptors as well. However, the expression of all isotypes of plasma membrane S1P receptors has been detected in HT-29 cells (data not shown).
It has yet to be determined whether these receptors play any role in mediating S1P-induced upregulation of COX-2 expression and PGE 2 production in HT-29 cells.
There were 7 adenocarcinomas that showed SK1 overexpression but exhibited no significant COX-2 immunostaining. This suggests that SK1 can be involved in colon carcinogenesis by a COX-2-independent mechanism as well. For example, it has been reported that basal SK1 function is necessary for the maintenance of tumor cell growth (29) . DNA damage agents induce tumor cell apoptosis in part by down-regulating SK1 expression (29) . In addition, inhibition of SK1 activity by a specific SK1 inhibitor induced tumor cell death in vitro and retarded the tumor growth in vivo (27) . Thus, we believe that further investigation of the role of SK1 in colon carcinogenesis may provide a novel molecular target for the development of mechanism-based chemopreventive and chemotherapeutic strategies against colon cancer. In fact, it has been reported that manipulation of dietary sphingolipids has the potential to protect against colorectal cancer development. It has yet to be determined whether the change in dietary sphingolipids prevents colon cancer development, in part, by down-regulating SK1 activity (30) (31) (32) (33) (34) .
In summary, this study provides the first evidence that SK1 expression is up-regulated by AOM in colon carcinogenesis, and the SK1/S1P pathway may be involved in regulation of the COX-2/PGE 2 pathway in colon cancer cells (Fig. 7) . It has yet to be determined whether SK1 may play a pivotal role in colon carcinogenesis in humans and whether SK1 constitutes a novel biomarker for colon cancer and molecular target for chemopreventive and therapeutic intervention against colon cancer development. 1 and 3) or pcDNA3-human SK1 (lanes 2 and 4) for 24 h were subjected to immunoblot analysis with the mouse anti-human SK1 monoclonal antibody. The antibody used to probe lanes 1 and 2 was preabsorbed with the immunizing SK1 oligopeptide, which resulted in the disappearance of the SK1 immunoblot band. Cross reactivity of the anti-human SK1 antibody to rat SK1: B) Western blot analysis was performed for the lysates from rat kidney (K) and colon (C) with the mouse anti-human SK1 monoclonal antibody, which also detected a single band with the respective molecular weight of rat SK1 (47 kD). SK1 immunostaining in rat colon cancer tissues SK1 expression. SK1 phosphorylates sphingosine to S1P. In turn, S1P may promote colon carcinogenesis via up-regulation of COX-2 expression and stimulation of PGE 2 production. In addition, the SK1/S1P pathway may also promote colon carcinogenesis via a COX-2 independent mechanism.
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